Each of these DC groups secrete specific types of cytokines that are specialized for priming and activating various classes of effector T cells and regulating particular stages of the cancer immune cycle; thus, in this way, they can affect the result of an immune response in different ways [49,202,203,205]; for example, cDC1s are specialized for antigen priming as well as their cross-presentations to the CD8+ T cells, followed by their recognition via MHC I signaling [202,206,207,208,209,210,211,212]. The gene discussed is CD8A; the disease is cancer.